Targeting Stat3 With G-Quartet Oligonucleotides in Metastic Prostate Cancer

reportActive / Technical Report | Accession Number: ADA455577 | Open PDF

Abstract:

During the three year funding period, we have well developed a novel and potent Stat3 inhibitor, which represents a promising class of anti-cancer drug in treatment of human cancers, including prostate, breast, head and neck, and long cancers. We appreciate to get a DOD funding for supporting this project. However, the funding period is too short to fulfill the preclinical drug development.

Author(s):
Jing, Naijie
Author Organization(s):
BAYLOR COLL OF MEDICINE HOUSTON TX
Descriptive Note:
Final rept. 1 Apr 2003-31 Mar 2006
Supplementary Note:
The original document contains color images. DOI: 10.21236/ADA455577
Pagination:
0046

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Contract/Grant Number(s):
DAMD17-03-1-0231
Monitor Series:
USAMRMC
 Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.3_Planning; JCA_1.2.3_Educating; JCA_1.2.5_Lessons Learned
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*PROSTATE CANCER, POTENCY, PROSTATE GLAND, CHEMOTHERAPEUTIC AGENTS, METASTASIS
Field(s)/Group(s):
Anatomy and Physiology, Medicine and Medical Research
Keyword(s):
*G QUARTET OLIGONUCLEOTIDES
Report Date:
2006 Apr 01
Creation Date:
2006 Oct 25